% Expired Patents = 40.0

EPO Patents = 2

Forward Citations = 32

Loading Chart...

2 inventors (with patents filed for the assignee):

Jon Amund Eriksen (5 out of 17 patents)

Gustav Gaudernack (1 out of 21 patents)

5 patents: Sort by Forward Citations

1. 10596239 - Peptide mixture (2020-03-24),

2. 10456457 - Peptide mixture (2019-10-29),

3. 10335473 - Peptide mixture (2019-07-02),

4. 9775892 - Peptide mixture (2017-10-03),

5. 9757439 - Peptide vaccine comprising mutant RAS peptide and chemotherapeutic agent (2017-09-12),

Company Overview

Targovax is a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients. The company focuses on oncolytic viruses, cancer vaccines, and immune modulating therapies to drive the immune system to recognize and destroy tumors. Targovax aims to improve patient outcomes by combining innovative science with a patient-centric approach.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

5 Patents

#101 in Oslo

#329 in Norway

Oslo, Norway

Targovax Asa

Forward Citations = 32

2 inventors:

Jon Amund Eriksen (5 out of 17 patents)

Gustav Gaudernack (1 out of 21 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Targovax Asa. Retrieved from https://idiyas.com/company/targovax-asa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

2 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]